Clinical trials: Women With Coagulation Disorders

Von Willebrand Diseases

Minimize Menorrhagia in Women With Von Willebrand Disease

• Terminated
• Age: 13 to 45 years
• Phase 3
• Results posted

This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda®) to minimize menorrhagia in women with von Willebrand disease…

Trial name

VWDMin (NCT02606045)

Testing

recombinant von Willebrand factor, tranexamic acid

Where

19 sites in United States

Volunteers

39 people

Sponsor

Margaret Ragni